Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Breast 1

Conditions

Hematologic Neoplasms 1Exanthema 1Breast Neoplasms 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has results × benralizumab × Clear all
NCT04552288 2026-06-01

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
51 enrolled 8 charts
Other hematologic neoplasm

Hematologic Neoplasms

NCT05966584 2024-08-29

A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
1 enrolled 5 charts
Breast

Breast Neoplasms, Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡